David Cibula - Gynecology

Author Information

David Cibula is affiliated with the Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic. He is a prominent figure in the field of gynecologic oncology, contributing significantly to both clinical practice and research.

Research Contributions

David Cibula has made substantial contributions to the field of gynecologic oncology. His research spans various aspects of gynecological malignancies, particularly focusing on areas such as ovarian cancer, cervical cancer, and endometrial cancer. Notable works include the exploration of the DNA methylome of cervical cells to predict ovarian cancer, assessments of preoperative staging techniques for ovarian cancer, and the development of recurrence prediction indices for early-stage cervical cancer. His studies often involve multi-center collaborations and randomized phase trials, contributing valuable insights into advanced treatment methodologies and diagnostic techniques.

Aliases

David Cibula is also known by the aliases D. Cibula and D Cibula.

Publication and Citation Metrics

Metric	Value
Publication Count	548
Citation Count	11439
H-index	55

Publications:

Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation

DOI: 10.1136/ijgc-2022-003397

Year: 2022

Extended pelvic resection for gynecological malignancies: A review of out-of-the-box surgery.

DOI: 10.1016/j.ygyno.2022.03.002

Year: 2022

VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

DOI: 10.1016/j.annonc.2022.02.223

Year: 2022

The DNA methylome of cervical cells can predict the presence of ovarian cancer

DOI: 10.1038/s41467-021-26615-y

Year: 2022

Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole‐body diffusion‐weighted MRI (ISAAC study)

DOI: 10.1002/uog.23654

Year: 2022

Quality of training in cervical cancer radical surgery: a survey from the European Network of Young Gynaecologic Oncologists (ENYGO)

DOI: 10.1136/ijgc-2021-002812

Year: 2022

SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer

DOI: 10.1245/s10434-022-11671-5

Year: 2022

SUCCOR cone study: conization before radical hysterectomy

DOI: 10.1136/ijgc-2021-002544

Year: 2022

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.

DOI: 10.1016/s1470-2045(22)00122-x

Year: 2022

Yolk Sac Tumor of the Omentum: A Case Report and Literature Review

DOI: 10.3390/diagnostics12020304

Year: 2022

What is Array Comparative Genomic Hybridization (aCGH)?

What is PTEN?

Who is a Good Candidate for Labia Augmentation?

What are the Treatment Options for Male Factor Infertility?

What are common reasons for claim denials in Gynecology?

What is CPT Code 59400?

What Factors Influence Medical Decisions in Gynecology?

What Types of Stretching Exercises Are Recommended?

How Effective is the Shirodkar Technique?

When is it Indicated?

Partnered Content Networks

Relevant Topics